Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 23 entries
Sorted by: Best Match Show Resources per page
Computational Analysis of the Mode of Action of Disopyramide and Quinidine on hERG-Linked Short QT Syndrome in Human Ventricles.

Frontiers in physiology

Whittaker DG, Ni H, Benson AP, Hancox JC, Zhang H.
PMID: 29085299
Front Physiol. 2017 Oct 04;8:759. doi: 10.3389/fphys.2017.00759. eCollection 2017.

The short QT syndrome (SQTS) is a rare cardiac disorder associated with arrhythmias and sudden death. Gain-of-function mutations to potassium channels mediating the rapid delayed rectifier current,

Cite
Whittaker DG, Ni H, Benson AP, et al. Computational Analysis of the Mode of Action of Disopyramide and Quinidine on hERG-Linked Short QT Syndrome in Human Ventricles. Front Physiol. 2017;8:759doi: 10.3389/fphys.2017.00759.
Whittaker, D. G., Ni, H., Benson, A. P., Hancox, J. C., & Zhang, H. (2017). Computational Analysis of the Mode of Action of Disopyramide and Quinidine on hERG-Linked Short QT Syndrome in Human Ventricles. Frontiers in physiology, 8759. https://doi.org/10.3389/fphys.2017.00759
Whittaker, Dominic G, et al. "Computational Analysis of the Mode of Action of Disopyramide and Quinidine on hERG-Linked Short QT Syndrome in Human Ventricles." Frontiers in physiology vol. 8 (2017): 759. doi: https://doi.org/10.3389/fphys.2017.00759
Whittaker DG, Ni H, Benson AP, Hancox JC, Zhang H. Computational Analysis of the Mode of Action of Disopyramide and Quinidine on hERG-Linked Short QT Syndrome in Human Ventricles. Front Physiol. 2017 Oct 04;8:759. doi: 10.3389/fphys.2017.00759. eCollection 2017. PMID: 29085299; PMCID: PMC5649182.
Copy Download .nbib Format: NLM
High pressure liquid chromatographic analysis of metoclopramide in serum.

Pharmaceutical research

Cohen JL, Hisayasu GH, Strum SB.
PMID: 24277185
Pharm Res. 1984 Jan;1(1):43-5. doi: 10.1023/A:1016334827197.

Metoclopramide has recently been approved at dose levels of 1 to 2 mg/kg for the treatment of nausea and vomiting resulting from cancer chemotherapeutic agents. A rapid, sensitive reverse phase HPLC quantitative procedure for metoclopramide in serum is described....

Cite
Cohen JL, Hisayasu GH, Strum SB. High pressure liquid chromatographic analysis of metoclopramide in serum. Pharm Res. 1984;1(1):43-5doi: 10.1023/A:1016334827197.
Cohen, J. L., Hisayasu, G. H., & Strum, S. B. (1984). High pressure liquid chromatographic analysis of metoclopramide in serum. Pharmaceutical research, 1(1), 43-5. https://doi.org/10.1023/A:1016334827197
Cohen, J L, et al. "High pressure liquid chromatographic analysis of metoclopramide in serum." Pharmaceutical research vol. 1,1 (1984): 43-5. doi: https://doi.org/10.1023/A:1016334827197
Cohen JL, Hisayasu GH, Strum SB. High pressure liquid chromatographic analysis of metoclopramide in serum. Pharm Res. 1984 Jan;1(1):43-5. doi: 10.1023/A:1016334827197. PMID: 24277185.
Copy Download .nbib Format: NLM
Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study.

JACC. Basic to translational science

Coppini R, Ferrantini C, Pioner JM, Santini L, Wang ZJ, Palandri C, Scardigli M, Vitale G, Sacconi L, Stefàno P, Flink L, Riedy K, Pavone FS, Cerbai E, Poggesi C, Mugelli A, Bueno-Orovio A, Olivotto I, Sherrid MV.
PMID: 31998849
JACC Basic Transl Sci. 2019 Oct 09;4(7):795-813. doi: 10.1016/j.jacbts.2019.06.004. eCollection 2019 Nov.

Disopyramide is effective and safe in patients with obstructive hypertrophic cardiomyopathy. However, its cellular and molecular mechanisms of action are unknown. We tested disopyramide in cardiomyocytes from the septum of surgical myectomy patients: disopyramide inhibits multiple ion channels, leading...

Cite
Coppini R, Ferrantini C, Pioner JM, et al. Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study. JACC Basic Transl Sci. 2019;4(7):795-813doi: 10.1016/j.jacbts.2019.06.004.
Coppini, R., Ferrantini, C., Pioner, J. M., Santini, L., Wang, Z. J., Palandri, C., Scardigli, M., Vitale, G., Sacconi, L., Stefàno, P., Flink, L., Riedy, K., Pavone, F. S., Cerbai, E., Poggesi, C., Mugelli, A., Bueno-Orovio, A., Olivotto, I., & Sherrid, M. V. (2019). Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study. JACC. Basic to translational science, 4(7), 795-813. https://doi.org/10.1016/j.jacbts.2019.06.004
Coppini, Raffaele, et al. "Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study." JACC. Basic to translational science vol. 4,7 (2019): 795-813. doi: https://doi.org/10.1016/j.jacbts.2019.06.004
Coppini R, Ferrantini C, Pioner JM, Santini L, Wang ZJ, Palandri C, Scardigli M, Vitale G, Sacconi L, Stefàno P, Flink L, Riedy K, Pavone FS, Cerbai E, Poggesi C, Mugelli A, Bueno-Orovio A, Olivotto I, Sherrid MV. Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study. JACC Basic Transl Sci. 2019 Oct 09;4(7):795-813. doi: 10.1016/j.jacbts.2019.06.004. eCollection 2019 Nov. PMID: 31998849; PMCID: PMC6978554.
Copy Download .nbib Format: NLM
Disopyramide as rescue treatment in a critically ill infant with obstructive hypertrophic cardiomyopathy refractory to beta blockers.

Journal of cardiology cases

Rodriguez-Gonzalez M, Castellano-Martinez A, Grujic B, Prieto-Heredia MA.
PMID: 30279782
J Cardiol Cases. 2017 Apr 14;15(6):209-213. doi: 10.1016/j.jccase.2017.03.004. eCollection 2017 Jun.

Hypertrophic obstructive cardiomyopathy (HOCM) is the most common known cause of sudden death in children beyond infancy and in young athletes. Cases reported indicate that steroid-induced HOCM is usually a benign disorder. The normalization of cardiac morphological changes and...

Cite
Rodriguez-Gonzalez M, Castellano-Martinez A, Grujic B, et al. Disopyramide as rescue treatment in a critically ill infant with obstructive hypertrophic cardiomyopathy refractory to beta blockers. J Cardiol Cases. 2017;15(6):209-213doi: 10.1016/j.jccase.2017.03.004.
Rodriguez-Gonzalez, M., Castellano-Martinez, A., Grujic, B., & Prieto-Heredia, M. A. (2017). Disopyramide as rescue treatment in a critically ill infant with obstructive hypertrophic cardiomyopathy refractory to beta blockers. Journal of cardiology cases, 15(6), 209-213. https://doi.org/10.1016/j.jccase.2017.03.004
Rodriguez-Gonzalez, Moises, et al. "Disopyramide as rescue treatment in a critically ill infant with obstructive hypertrophic cardiomyopathy refractory to beta blockers." Journal of cardiology cases vol. 15,6 (2017): 209-213. doi: https://doi.org/10.1016/j.jccase.2017.03.004
Rodriguez-Gonzalez M, Castellano-Martinez A, Grujic B, Prieto-Heredia MA. Disopyramide as rescue treatment in a critically ill infant with obstructive hypertrophic cardiomyopathy refractory to beta blockers. J Cardiol Cases. 2017 Apr 14;15(6):209-213. doi: 10.1016/j.jccase.2017.03.004. eCollection 2017 Jun. PMID: 30279782; PMCID: PMC6149641.
Copy Download .nbib Format: NLM
Restoring Sinus Rhythm in Patients With Atrial Flutter and Fibrillation: Pharmacologic or Electrical Cardioversion?.

Journal of cardiovascular pharmacology and therapeutics

Gallik D, Altamirano J, Singh BN.
PMID: 10684451
J Cardiovasc Pharmacol Ther. 1997 Apr;2(2):135-144. doi: 10.1177/107424849700200207.

Atrial fibrillation and atrial flutter, the most frequently encountered tachyarrhythmias requiring treatment, have become a major focus for clinical and basic research in recent years. Restoration and maintenance of sinus rhythmn, having been shown to improve exercise capacity, alleviate...

Cite
Gallik D, Altamirano J, Singh BN. Restoring Sinus Rhythm in Patients With Atrial Flutter and Fibrillation: Pharmacologic or Electrical Cardioversion?. J Cardiovasc Pharmacol Ther. 1997;2(2):135-144doi: 10.1177/107424849700200207.
Gallik, D., Altamirano, J., & Singh, B. N. (1997). Restoring Sinus Rhythm in Patients With Atrial Flutter and Fibrillation: Pharmacologic or Electrical Cardioversion?. Journal of cardiovascular pharmacology and therapeutics, 2(2), 135-144. https://doi.org/10.1177/107424849700200207
Gallik, et al. "Restoring Sinus Rhythm in Patients With Atrial Flutter and Fibrillation: Pharmacologic or Electrical Cardioversion?." Journal of cardiovascular pharmacology and therapeutics vol. 2,2 (1997): 135-144. doi: https://doi.org/10.1177/107424849700200207
Gallik D, Altamirano J, Singh BN. Restoring Sinus Rhythm in Patients With Atrial Flutter and Fibrillation: Pharmacologic or Electrical Cardioversion?. J Cardiovasc Pharmacol Ther. 1997 Apr;2(2):135-144. doi: 10.1177/107424849700200207. PMID: 10684451.
Copy Download .nbib Format: NLM
Disopyramide for Hypertrophic Cardiomyopathy.

Cureus

Sanchez-Nadales A, Anampa-Guzmán A, Khan A.
PMID: 31263635
Cureus. 2019 Apr 23;11(4):e4526. doi: 10.7759/cureus.4526.

Hypertrophic cardiomyopathy (HCM) is a cardiac disease characterized by hypertrophy of a nondilated left ventricle without any other cardiac or systemic disease that could account for observed hypertrophy. We present a female patient with the diagnosis of obstructive HCM,...

Cite
Sanchez-Nadales A, Anampa-Guzmán A, Khan A. Disopyramide for Hypertrophic Cardiomyopathy. Cureus. 2019;11(4):e4526doi: 10.7759/cureus.4526.
Sanchez-Nadales, A., Anampa-Guzmán, A., & Khan, A. (2019). Disopyramide for Hypertrophic Cardiomyopathy. Cureus, 11(4), e4526. https://doi.org/10.7759/cureus.4526
Sanchez-Nadales, Alejandro, et al. "Disopyramide for Hypertrophic Cardiomyopathy." Cureus vol. 11,4 (2019): e4526. doi: https://doi.org/10.7759/cureus.4526
Sanchez-Nadales A, Anampa-Guzmán A, Khan A. Disopyramide for Hypertrophic Cardiomyopathy. Cureus. 2019 Apr 23;11(4):e4526. doi: 10.7759/cureus.4526. PMID: 31263635; PMCID: PMC6592455.
Copy Download .nbib Format: NLM
Hypertrophic Cardiomyopathy.

Cardiac electrophysiology clinics

Critoph C, Elliott P.
PMID: 28770721
Card Electrophysiol Clin. 2010 Dec;2(4):587-598. doi: 10.1016/j.ccep.2010.09.010.

Hypertrophic cardiomyopathy is a myocardial disease characterized by myocardial hypertrophy, disorganization of cardiac myocytes, and fibrosis. Twenty-five percent of patients have a dynamic left ventricular outflow tract gradient caused by the combined effects of rapid ventricular ejection, a narrowed...

Cite
Critoph C, Elliott P. Hypertrophic Cardiomyopathy. Card Electrophysiol Clin. 2010;2(4):587-598doi: 10.1016/j.ccep.2010.09.010.
Critoph, C., & Elliott, P. (2010). Hypertrophic Cardiomyopathy. Cardiac electrophysiology clinics, 2(4), 587-598. https://doi.org/10.1016/j.ccep.2010.09.010
Critoph, Christopher, and Elliott, Perry. "Hypertrophic Cardiomyopathy." Cardiac electrophysiology clinics vol. 2,4 (2010): 587-598. doi: https://doi.org/10.1016/j.ccep.2010.09.010
Critoph C, Elliott P. Hypertrophic Cardiomyopathy. Card Electrophysiol Clin. 2010 Dec;2(4):587-598. doi: 10.1016/j.ccep.2010.09.010. PMID: 28770721.
Copy Download .nbib Format: NLM
Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management.

Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC

Tisdale JE.
PMID: 27212965
Can Pharm J (Ott). 2016 May;149(3):139-52. doi: 10.1177/1715163516641136. Epub 2016 Apr 08.

Torsades de pointes (TdP) is a life-threatening arrhythmia associated with prolongation of the corrected QT (QTc) interval on the electrocardiogram. More than 100 drugs available in Canada, including widely used antibiotics, antidepressants, cardiovascular drugs and many others, may cause...

Cite
Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016;149(3):139-52doi: 10.1177/1715163516641136.
Tisdale, J. E. (2016). Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC, 149(3), 139-52. https://doi.org/10.1177/1715163516641136
Tisdale, James E. "Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management." Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC vol. 149,3 (2016): 139-52. doi: https://doi.org/10.1177/1715163516641136
Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016 May;149(3):139-52. doi: 10.1177/1715163516641136. Epub 2016 Apr 08. PMID: 27212965; PMCID: PMC4860751.
Copy Download .nbib Format: NLM
Evaluation and treatment of pediatric patients with neurocardiogenic syncope.

Progress in pediatric cardiology

Sokoloski MC.
PMID: 11457681
Prog Pediatr Cardiol. 2001 Aug;13(2):127-131. doi: 10.1016/s1058-9813(01)00095-9.

Neurocardiogenic syncope is the most common form of syncope in children. The most widely accepted mechanism of its etiology is a vigorous contraction of the heart due to relative hypovolemia leading to stimulation of C-fibers and sympathetic withdrawal. Episodes...

Cite
Sokoloski MC. Evaluation and treatment of pediatric patients with neurocardiogenic syncope. Prog Pediatr Cardiol. 2001;13(2):127-131doi: 10.1016/s1058-9813(01)00095-9.
Sokoloski, M. C. (2001). Evaluation and treatment of pediatric patients with neurocardiogenic syncope. Progress in pediatric cardiology, 13(2), 127-131. https://doi.org/10.1016/s1058-9813(01)00095-9
Sokoloski, M C.. "Evaluation and treatment of pediatric patients with neurocardiogenic syncope." Progress in pediatric cardiology vol. 13,2 (2001): 127-131. doi: https://doi.org/10.1016/s1058-9813(01)00095-9
Sokoloski MC. Evaluation and treatment of pediatric patients with neurocardiogenic syncope. Prog Pediatr Cardiol. 2001 Aug;13(2):127-131. doi: 10.1016/s1058-9813(01)00095-9. PMID: 11457681.
Copy Download .nbib Format: NLM
Medical, surgical and interventional management of hypertrophic cardiomyopathy with obstruction.

Current treatment options in cardiovascular medicine

Elmariah S, Fifer MA.
PMID: 22956194
Curr Treat Options Cardiovasc Med. 2012 Dec;14(6):665-78. doi: 10.1007/s11936-012-0206-5.

OPINION STATEMENT: Patients with hypertrophic cardiomyopathy (HCM) are classified as having hypertrophic obstructive cardiomyopathy (HOCM) if a left ventricular outflow tract (LVOT) gradient is present at rest or during provocation, as with Valsalva maneuver or exercise. Management of HCM...

Cite
Elmariah S, Fifer MA. Medical, surgical and interventional management of hypertrophic cardiomyopathy with obstruction. Curr Treat Options Cardiovasc Med. 2012;14(6):665-78doi: 10.1007/s11936-012-0206-5.
Elmariah, S., & Fifer, M. A. (2012). Medical, surgical and interventional management of hypertrophic cardiomyopathy with obstruction. Current treatment options in cardiovascular medicine, 14(6), 665-78. https://doi.org/10.1007/s11936-012-0206-5
Elmariah, Sammy, and Fifer, Michael A. "Medical, surgical and interventional management of hypertrophic cardiomyopathy with obstruction." Current treatment options in cardiovascular medicine vol. 14,6 (2012): 665-78. doi: https://doi.org/10.1007/s11936-012-0206-5
Elmariah S, Fifer MA. Medical, surgical and interventional management of hypertrophic cardiomyopathy with obstruction. Curr Treat Options Cardiovasc Med. 2012 Dec;14(6):665-78. doi: 10.1007/s11936-012-0206-5. PMID: 22956194.
Copy Download .nbib Format: NLM
Ionic Mechanisms of Disopyramide Prolonging Action Potential Duration in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1.

Frontiers in pharmacology

Lan H, Xu Q, El-Battrawy I, Zhong R, Li X, Lang S, Cyganek L, Borggrefe M, Zhou X, Akin I.
PMID: 33154722
Front Pharmacol. 2020 Oct 12;11:554422. doi: 10.3389/fphar.2020.554422. eCollection 2020.

Short QT syndrome (SQTS) is associated with tachyarrhythmias and sudden cardiac death. So far, only quinidine has been demonstrated to be effective in patients with SQTS type 1(SQTS1). The aim of this study was to investigate the mechanisms of...

Cite
Lan H, Xu Q, El-Battrawy I, et al. Ionic Mechanisms of Disopyramide Prolonging Action Potential Duration in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1. Front Pharmacol. 2020;11:554422doi: 10.3389/fphar.2020.554422.
Lan, H., Xu, Q., El-Battrawy, I., Zhong, R., Li, X., Lang, S., Cyganek, L., Borggrefe, M., Zhou, X., & Akin, I. (2020). Ionic Mechanisms of Disopyramide Prolonging Action Potential Duration in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1. Frontiers in pharmacology, 11554422. https://doi.org/10.3389/fphar.2020.554422
Lan, Huan, et al. "Ionic Mechanisms of Disopyramide Prolonging Action Potential Duration in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1." Frontiers in pharmacology vol. 11 (2020): 554422. doi: https://doi.org/10.3389/fphar.2020.554422
Lan H, Xu Q, El-Battrawy I, Zhong R, Li X, Lang S, Cyganek L, Borggrefe M, Zhou X, Akin I. Ionic Mechanisms of Disopyramide Prolonging Action Potential Duration in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1. Front Pharmacol. 2020 Oct 12;11:554422. doi: 10.3389/fphar.2020.554422. eCollection 2020. PMID: 33154722; PMCID: PMC7586889.
Copy Download .nbib Format: NLM
Drug Therapy for Vagally-Mediated Atrial Fibrillation and Sympatho-Vagal Balance in the Genesis of Atrial Fibrillation: A Review of the Current Literature.

Journal of atrial fibrillation

Rattanawong P, Kewcharoen J, S Srivathsan K, Shen WK.
PMID: 33024510
J Atr Fibrillation. 2020 Jun 30;13(1):2410. doi: 10.4022/jafib.2410. eCollection 2020.

OBJECTIVE: The presence of both sympathetic activation-mediated triggers and parasympathetic activation-mediated substrates are required to initiate and maintain some forms of atrial fibrillation (AF). AF predominantly precipitated by parasympathetic stimulation is known as vagally-mediated AF (VM-AF). The role of...

Cite
Rattanawong P, Kewcharoen J, S Srivathsan K, et al. Drug Therapy for Vagally-Mediated Atrial Fibrillation and Sympatho-Vagal Balance in the Genesis of Atrial Fibrillation: A Review of the Current Literature. J Atr Fibrillation. 2020;13(1):2410doi: 10.4022/jafib.2410.
Rattanawong, P., Kewcharoen, J., S Srivathsan, K., & Shen, W. K. (2020). Drug Therapy for Vagally-Mediated Atrial Fibrillation and Sympatho-Vagal Balance in the Genesis of Atrial Fibrillation: A Review of the Current Literature. Journal of atrial fibrillation, 13(1), 2410. https://doi.org/10.4022/jafib.2410
Rattanawong, Pattara, et al. "Drug Therapy for Vagally-Mediated Atrial Fibrillation and Sympatho-Vagal Balance in the Genesis of Atrial Fibrillation: A Review of the Current Literature." Journal of atrial fibrillation vol. 13,1 (2020): 2410. doi: https://doi.org/10.4022/jafib.2410
Rattanawong P, Kewcharoen J, S Srivathsan K, Shen WK. Drug Therapy for Vagally-Mediated Atrial Fibrillation and Sympatho-Vagal Balance in the Genesis of Atrial Fibrillation: A Review of the Current Literature. J Atr Fibrillation. 2020 Jun 30;13(1):2410. doi: 10.4022/jafib.2410. eCollection 2020. PMID: 33024510; PMCID: PMC7533140.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 23 entries